Business
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
THOUSAND OAKS, Calif., Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International
About this update from Amgen Inc.
[{"type":"text","content":"THOUSAND OAKS, Calif., Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) on Sunday, Sept. 8, at 8 a.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will participate to discuss Amgen's oncology program, including data being presented at WCLC for the Company's KRASG12C inhibitor AMG 510. \nLive audio of the investor call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. \nThe webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. \nAbout AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\nAmgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.\nFor more information, visit www.amgen.com and follow us on www.twitter.com/amgen.\nCONTACT: Amgen, Thousand OaksJessica Akopyan, 805-447-0974 (media) Trish Hawkins, 805-447-5631 (media)Arvind Sood, 805-447-1060 (investors)\n \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-iaslc-2019-world-conference-on-lung-cancer-300911897.html\nSOURCE Amgen\n\...